Avalo Therapeutics (AVTX) EBITDA Margin Growth (1y) (2017 - 2025)
Powered by 
Analysis
Avalo Therapeutics (AVTX) EBITDA Margin Growth (1y) (2017 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -1,651.00 |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 29,091.00 |
| 10 | Avalo Therapeutics | 835.85 Mn | 835.85 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -2.65 Mn |
| Dec 31, 2024 | -559,166.00 |
| Sep 30, 2024 | -357,608.00 |
| Dec 31, 2023 | -35,287.00 |
| Sep 30, 2023 | -161,638.00 |
| Jun 30, 2023 | 3,304.00 |
| Mar 31, 2023 | -7,320.00 |
| Dec 31, 2022 | 721,400.00 |
| Sep 30, 2022 | 124,687.00 |
| Jun 30, 2022 | -63,446.00 |
| Mar 31, 2022 | 468,737.00 |
| Dec 31, 2021 | -711,083.00 |
| Sep 30, 2021 | -2,443.00 |
| Jun 30, 2021 | 37,248.00 |
| Mar 31, 2021 | -532,448.00 |
| Dec 31, 2020 | -10,613.00 |
| Sep 30, 2020 | -106,505.00 |
| Jun 30, 2020 | -70,103.00 |
| Mar 31, 2020 | -94,813.00 |
| Dec 31, 2019 | -101,000.00 |